Skip to main content
Premium Trial:

Request an Annual Quote

DoD Earmarks $1.5M for Southeast Nebraska Cancer Center s Personalized Medicine Network

NEW YORK, Dec. 20 (GenomeWeb News) - The Southeast Nebraska Cancer Center said today that it is slated to receive $1.5 million in US Department of Defense appropriations for the current fiscal year to support a network and database of cancer patients' tissue samples.


The center, based in Lincoln, Neb., said that it will be part of the DoD's National Functional Genomics Center, and that it will use the funding to create a network to collect cancer tissue samples and to follow the patients' progress through therapy, which would be merged into a national database.


The system will allow personalized cancer treatment decisions based on patients' molecular profiles, the center said.


"This research will help us identify genomic sequence changes associated with cancer in individual patients," said Mark Carlson of the Southeast Nebraska Cancer Center. "Our hope for the future is that your doctor can run a simple test on a small tumor sample and use a quick genetic analysis to tailor the best therapy for you as an individual."

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.